Jazz Pharma Plc (JAZZ)
$147.88 2.02 (1.35%)
17:55 EST JAZZ Stock Quote Delayed 15 Minutes
Previous Close $147.88
Market Cap 8.56B
PE Ratio 20.26
Volume (Avg. Vol.) 527,600
Day's Range 147.55 - 150.38
52-Week Range 113.52 - 153.03
Dividend & Yield N/A (N/A)
JAZZ Stock Predictions, Articles, and Jazz Pharma Plc News
- From InvestorPlace
- From the Web
These ten growth stocks saw the highest percentage growth over the last decade, and some remain unknown to investors despite huge increases.
Big biotech buyouts have already started happening. These five biotech stocks could be the next to go.
P/B ratio is a convenient tool to identify low-priced stocks that have high-growth prospects. Here are five stocks with low P/B ratios.
These five biotech stocks balance low valuation with high growth and a track record of profits.
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects. Compare Brokers....
Jazz Pharmaceuticals stock is hovering around breakeven after agreeing to acquire Celator (CPXX) for a 73% premium. Does the deal make sense?
Was 2015 the final nail in the coffin for buy-and-hold investing? Not necessarily. Buy these 7 names and hold for 2016 before letting them go
While the rest of the market is enjoying a healthy start to the fall, biopharma stocks continue to lag. Here are 5 pharma stocks on sale now
Jazz Pharmaceuticals, bluebird bio, Illumina and Celgene are the latest batch of biotech stocks worth serious consideration.
By Jeff Reeves
The S&P has roughly doubled in the past five years, but these 10 stocks blow that performance out of the water, with gains of 1,500% or more.
Two of Jazz Pharmaceuticals' drugs are showing record growth, and the stock just keeps making new highs. Can it last?
This week, five Pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").
Navellier RatingsPowered by Portfolio Grader